Shanghai, CHINA — March 25, 2025 — Beyang Therapeutics Co., Ltd., a clinical-stage AI-driven biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BT01001, a first-in-class ophthalmic solution for the treatment of diabetic retinopathy (DR). The IND clearance marks a major milestone for Beyang in the development of innovative treatments for diabetic retinopathy.

Shanghai, China–February 21, 2025—Beyang Therapeutics, a clinical-stage biotechnology company dedicated to developing innovative treatments for retinal diseases, has announced today the submission of an Investigational New Drug (IND) application of BT01001, a novel ophthalmic solution for the treatment of diabetic retinopathy (DR), to the U.S. Food and Drug Administration (FDA).

Beyang Therapeutics recently presented its second-generation menin inhibitor, BTC-86, at the 66th Annual Meeting of the American Society of Hematology (ASH). BTC-86 has demonstrated remarkable advantages over the first-generation menin inhibitor, Revumenib, including overcoming resistance mutations and minimizing QTc prolongation. These breakthroughs have garnered significant attention from hematological oncologists, experts, and industry leaders worldwide.

Shanghai, China, December 10th, 2024 – Beyang Therapeutics announced today that, it has become a resident of Johnson & Johnson Innovation – JLABS @ Shanghai (‘JLABS’). Beyang aims to be a global leader in ophthalmic drugs and offer non-invasive treatment options for patients with retinal diseases.

Beyang Therapeutics has successfully secured significant pre-Series A+ funding from Root Venture Partners. This infusion of capital will empower Beyang Therapeutics to further advance its cutting-edge research and development initiatives in the fields of ophthalmology and oncology. The company's innovative approach and promising pipeline of therapeutic solutions position it as a key player in revolutionizing treatments for complex medical conditions.

Beyang Therapeutics has recently secured significant pre-Series A financing, led by Ming Bioventures, a renowned venture capital firm specializing in life sciences investments. This funding will enable Beyang Therapeutics to advance its diverse pipeline of projects, with a focus on accelerating the development of existing projects and expanding its portfolio through strategic collaborations.

Beyang won the MIT Technology Review China's 2nd Life Science Entrepreneurship Competition, Best Team Award.

On December 29, 2022, the 5th Guangdong-Hong Kong-Macao Greater Bay Area Top 50 Biotechnology Innovative Enterprises Award Ceremony was held in Nansha, Guangzhou, during which the Top 50 Biotechnology Innovative Enterprises List was officially announced.

In September 2021, Beyang Therapeutics completed an angel round financing of tens of millions of RMB. The financing was led by Oriza Holdings, and co-invested by Yuanbio Venture Capital, Baidu Ventures, and Elink Ventures.